Navarrete, Carmen
García-Martín, Adela
Correa-Sáez, Alejandro
Prados, María E.
Fernández, Francisco
Pineda, Rafael
Mazzone, Massimiliano
Álvarez-Benito, Marina
Calzado, Marco A.
Muñoz, Eduardo
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PID2020-114753RB-I00, PID2020-114753RB-I00, PID2020-114753RB-I00)
Junta de A (P18-RTJ-4163)
Article History
Received: 7 March 2022
Accepted: 30 June 2022
First Online: 9 July 2022
Declarations
:
: The animal model was performed in strict accordance with the European Union (EU) and governmental regulations. Handling of animals was performed in compliance with the guidelines of animal care set by the EU guidelines 86/609/EEC, and the Ethic Committee on Animal Experimentation at the University of Córdoba (UCO, Córdoba, Spain) approved all the procedures described in this study (2020PI/14) for TBI and 2018PI/03 for Angiogenesis in vivo model.
: Not applicable.
: Carmen Navarrete and Adela García-Martín are employees of Emerald Health Pharmaceuticals. Eduardo Muñoz is Chief Scientific Officer of Emerald Health Pharmaceuticals.